8-K: Vaxart Secures $453 Million BARDA Funding for Phase 2b COVID-19 Oral Vaccine Trial

Vaxart has been awarded up to $453 million by BARDA to conduct a Phase 2b trial comparing its oral COVID-19 vaccine pill against an approved mRNA vaccine.

Summary

• Vaxart has entered into a Project Agreement with Advanced Technology International, funded by BARDA, to receive up to $453 million for a Phase 2b trial of its oral COVID-19 vaccine.
• The initial award is approximately $65.7 million, with $64.7 million as a fixed fee and the remainder for trial preparation costs.
• Additional funding of up to $387.2 million is contingent on BARDA and Vaxart deciding to continue the trial.
• The Phase 2b trial will compare Vaxart's oral pill vaccine against an FDA-approved mRNA vaccine in 10,000 adults, with 5,000 in each group.
• At least 25% of participants will be 65 years or older.
• The trial will measure efficacy for symptomatic and asymptomatic disease, immune responses, and adverse events.
• The primary endpoint is the relative efficacy of Vaxart's vaccine in preventing symptomatic disease, with analysis occurring 12 months post-vaccination or after 255 events.

Sentiment

Score: 8

Explanation: The document is very positive due to the significant funding secured from BARDA, which will enable a large Phase 2b trial. The potential for a successful oral vaccine is also a positive factor. However, the contingent nature of the additional funding and the inherent risks of clinical trials prevent a perfect score.

Positives

• The funding of up to $453 million from BARDA significantly supports Vaxart's clinical development program.
• The Phase 2b trial will provide a direct comparison of Vaxart's oral vaccine against an approved mRNA vaccine.
• Vaxart's oral vaccine platform offers potential advantages in terms of storage, distribution, and administration.
• The study includes a large sample size of 10,000 participants, enhancing the statistical power of the results.
• The study will measure both symptomatic and asymptomatic disease, providing a comprehensive assessment of vaccine efficacy.

Negatives

• The additional $387.2 million in funding is contingent on BARDA and Vaxart agreeing to continue the trial, creating uncertainty.
• The trial is a comparative study, meaning the success of Vaxart's vaccine is dependent on its performance relative to an existing mRNA vaccine.
• The primary efficacy analysis will not be performed until 12 months post-vaccination, which is a long time to wait for results.
• The company is still in the clinical stage and has not yet brought a product to market.

Risks

• The company's ability to achieve milestones and deliverables under the Project Agreement is subject to risks and uncertainties.
• The success of the Phase 2b trial is not guaranteed, and results may not be favorable.
• The company is subject to risks associated with clinical trials, regulatory approvals, and commercialization.
• The company has a history of operating losses, which may continue.
• The company may face challenges in scaling up production of its oral vaccine.

Future Outlook

The company anticipates initiating enrollment for the Phase 2b trial as early as summer 2024 and expects an interim analysis for vaccine efficacy in the first quarter of 2025. The company will continue to develop its oral vaccine platform for other infectious diseases.

Management Comments

• Dr. James F. Cummings, Vaxart's Chief Medical Officer, stated that the funding will enable Vaxart to conduct a Phase 2b trial for their COVID-19 oral pill vaccine candidate and explore the results of a head-to-head comparison with an mRNA vaccine.
• Steven Lo, Vaxart's Chief Executive Officer, believes their oral pill vaccine platform can better meet societal needs for COVID-19 and other infectious diseases and that this funding will assist in determining whether they can bring a transformational, next-generation approach to global vaccination.

Industry Context

This announcement is significant as it highlights the ongoing efforts to develop next-generation COVID-19 vaccines, particularly those that offer advantages over traditional injectable vaccines. The funding from BARDA underscores the importance of innovative vaccine technologies in addressing current and future pandemic threats. Vaxart's oral vaccine platform is a novel approach that could potentially disrupt the vaccine market.

Comparison to Industry Standards

• The Phase 2b trial is designed to compare Vaxart's oral vaccine directly against an approved mRNA vaccine, setting a high bar for efficacy.
• Companies like Moderna and Pfizer have established mRNA vaccines as the standard for COVID-19 prevention, making this a challenging comparison.
• Vaxart's oral vaccine platform is unique compared to the injectable vaccines of competitors, offering potential advantages in terms of ease of administration and distribution.
• The large sample size of 10,000 participants is comparable to other large-scale vaccine trials, ensuring robust statistical analysis.
• The study's focus on both symptomatic and asymptomatic disease is in line with current best practices for evaluating vaccine efficacy.

Stakeholder Impact

• Shareholders will likely view the BARDA funding positively, as it significantly de-risks the company's clinical development program.
• Employees will be involved in the execution of the Phase 2b trial, which could lead to job growth and development opportunities.
• Customers (potential patients) may benefit from a successful oral vaccine, which could be more convenient and accessible than injectable vaccines.
• Suppliers may see increased demand for materials and services related to the trial and vaccine production.
• Creditors may view the funding as a positive sign of the company's financial stability.

Next Steps

• Vaxart will initiate enrollment for the Phase 2b trial as early as summer 2024.
• The company will continue to work with BARDA to secure the additional funding for the trial.
• Vaxart will conduct an interim analysis of the trial data as early as the first quarter of 2025.
• The company will continue to develop its oral vaccine platform for other infectious diseases.

Key Dates

Keywords

Vaxart, BARDA, COVID-19, oral vaccine, Phase 2b trial, mRNA vaccine, clinical trial, vaccine development, infectious diseases, Project NextGen